Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial Results on November 13, 2025

Venus Concept Inc. (NASDAQ: VERO), a prominent figure in the medical aesthetic technology sector, has announced that it will release its financial results for the third quarter of fiscal year 2025 on November 13, 2025, prior to the market opening. This occasion is significant as investors and stakeholders will gain insights into the company’s performance and strategic direction during this period.

Management will hold a conference call on the same day at 8:00 a.m. Eastern Time, where they will discuss the quarterly results and address questions from participants. Those interested in joining the call can dial 877-407-2991 (international callers should use +1 201-389-0925) and must provide the access code 13756285. Additionally, a live webcast of the conference call will be accessible through the investor relations section of the company’s website, enhancing broader participation.

For individuals unable to attend the live call, a replay will be available for two weeks, providing an opportunity to catch up on the discussions. The replay can be accessed by dialing 877-660-6853 (or 201-612-7415 for international callers) with the same access code.

Venus Concept stands out in the medical aesthetics industry with its extensive range of product offerings, including minimally invasive and non-invasive technologies for aesthetic procedures and hair restoration. Their devices, such as Venus Versa and NeoGraft®, are designed to meet the growing demand in over 60 countries. The company’s backing by prominent growth equity investors reinforces its position in the market and showcases its potential for continued innovation and expansion.

For investor relations inquiries, Mike Piccinino, CFA, can be contacted via email at VenusConceptIR@ICRHealthcare.com.

As Venus Concept Inc. (NASDAQ: VERO) prepares to release its third quarter financial results for fiscal year 2025 on November 13, market participants should be strategic in their approach to this upcoming announcement. Given that Venus Concept is a leader in the global medical aesthetic technology market, analysts will closely scrutinize the results for indications of growth trends, particularly in its diverse product portfolio that includes both minimally invasive and non-invasive systems.

Investors should pay special attention to reported sales figures from key product lines like Venus Versa and the ARTAS iX® Robotic Hair Restoration system. Increased revenue from these platforms could signal robust demand, which would be a positive catalyst for stock performance. Furthermore, market conditions and consumer spending within the aesthetic sector are crucial factors; thus, any commentary from management regarding macroeconomic trends or shifts in consumer behavior could influence short-term stock movements.

Moreover, the conference call slated for 8:00 a.m. ET will be particularly telling. This platform will provide investors with insights into management's outlook for the remainder of the fiscal year, including guidance on future sales and capital deployment plans. Investors should also look out for forward-looking statements that might indicate new product innovations or expansions into new markets, as these could enhance growth potential.

Lastly, with Venus Concept backed by notable healthcare investors, confidence in the company's strategic direction and potential resilience in challenging economic environments may bolster investor sentiment. Therefore, it’s advisable for investors to consider taking positions before the earnings release, while remaining mindful of the volatility that often accompanies earnings announcements. Staying informed about any shifts in the aesthetic healthcare landscape will be essential for making well-rounded investment decisions post-announcement.